Augmented antitumor effects of erlotinib and cabozantinib on A549 non-small cell lung cancer: In vitro and in vivo studies

Augmented antitumor effects of erlotinib and cabozantinib on A549 non-small cell lung cancer: In vitro and in vivo studies

Non-small cell lung carcinoma is a challenging disease worldwide. This study aims to determine whether combining erlotinib, an epidermal growth factor receptor (EGFR) inhibitor, with cabozantinib, a mesenchymal-epithelial transition factor (c-Met) inhibitor, would have an augmented therapeutic benef...

Full description

Bibliographic Details
Main Authors: Khalid Alhazzani, Meshal Alsahli, Ahmed Z Alanazi, Mohammad Algahtani, Ahmad A Alenezi, Ali Alhoshani, Mohammed Alqinyah, Abdullah S. Alhamed, Khaled Alhosaini
Format: Article
Language:English
Published: Elsevier 2023-10-01
Series:Saudi Pharmaceutical Journal
Subjects:
Erlotinib
Cabozantinib
VEGF
EGFR
Combination therapy
A549
Online Access:http://www.sciencedirect.com/science/article/pii/S1319016423002517

Internet

http://www.sciencedirect.com/science/article/pii/S1319016423002517

Similar Items